If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  CoSeal® Surgical Sealant Shown to Inhibit Adhesions in Cardiac Procedures PALO ALTO, CA -- September 20, 2001 -- Cohesion Technologies Inc., a leader in developing and commercializing BioSurgical products including surgical hemostats, sealants, adhesion prevention barriers and adhesives, today announced that CoSeal® surgical sealant was shown to significantly reduce the formation, tenacity and surface area of adhesions during cardiac surgery in preclinical models. The results of this study were published in Heart Surgery Forum by lead author Marc Hendrikx, M.D., Ph.D., Department of Cardiothoracic and Vascular Surgery, Jesse Hospital, in Hasselt, Belgium, in an article entitled "Evaluation of a Novel Synthetic Sealant for Inhibition of Cardiac Adhesions and Clinical Experience in Cardiac Surgery Procedures." In the study, CoSeal was compared with an approved fibrin glue and with a surgical control. Eighty-eight percent of CoSeal treated sites had no adhesions or had adhesions of low tenacity. In comparison, zero percent of the fibrin glue treated sites and 13 percent of surgical control sites had either no adhesions or adhesions of low tenacity. In addition, CoSeal significantly reduced the percentage of treatment area with adhesions as compared with the fibrin glue and the surgical control. Commenting on the study, Dr. Hendrikx said, "We were amazed by the adhesion prevention properties exhibited by CoSeal in the study. The results were very impressive. In addition, we observed that CoSeal also sealed vascular grafts very effectively. Based on our work, CoSeal seems to have multiple important applications during cardiac surgery, addressing problems for which we currently have few therapeutic options." Pericardial adhesions subject patients requiring re-operation to potential injuries to the heart, great vessels, and cardiac grafts during the re-sternotomy. These adhesions can severely complicate re-operations by making re-entry hazardous, impeding orientation and visibility, increasing the loss of blood, and prolonging the operating time. "CoSeal has demonstrated significant potential in preclinical testing as an effective adhesion prevention barrier," stated Frank DeLustro, Ph.D., president and chief operating officer of Cohesion. "CoSeal's synthetic composition, quick and easy preparation and ability to adhere to tissue where it is applied and remain in place during the critical wound-healing period, could offer significant competitive advantages over the limited and cumbersome alternatives available today." CoSeal is currently marketed as a surgical sealant in certain countries of Europe and in Australia. CoSeal is a completely synthetic, self-polymerizing liquid biomaterial that resorbs in less than 30 days. CoSeal, which can be prepared in less than two minutes, is easy to apply and adheres effectively to tissue to seal around synthetic surgical materials such as Dacron and PTFE. These product attributes are expected to provide significant competitive advantages in the crowded and hectic operating room setting. SOURCE: Cohesion Technologies, Inc.
|
